Zumutor Biologics

Bengaluru, India Founded: 2013 • Age: 13 yrs
Zumutor Biologics is focused on developing novel immunotherapies.

About Zumutor Biologics

Zumutor Biologics is a Healthcare company based in Bengaluru (India) founded in 2013 by Kavitha Iyer Rodrigues. Zumutor Biologics is focused on developing novel immunotherapies. It operates on a HealthTech model. Zumutor Biologics has raised $35.19 million across 9 funding rounds from investors including Accel, Bharat Fund and Aarin Capital. The company has 23 employees. Its chief executive, as recorded, is Kavitha Iyer Rodrigues. Its Indian entity Zumutor Biologics Private Limited reported revenue of β‚Ή4.63 Cr. Zumutor Biologics offers products and services including ZM008 and Monoclonal Antibodies. Its focus areas include Biotechnology and Immuno-Oncology.

Company details

Zumutor Biologics is engaged in the discovery and development of novel drug products, particularly in the field of immuno-oncology. The company specializes in targeted NK cell therapeutics using proprietary human antibody platforms like INABLR. Headquartered in Cambridge, MA, USA, with RD facilities in Bangalore, India, Zumutor is involved in creating first-in-class therapeutic antibodies that address innate immunity and tumor microenvironments. Additionally, bespoke services are offered to facilitate partners discovery programs and co-development of monoclonal antibodies.

  • Headquarters Bengaluru, India
  • Employees 23
  • Founders Kavitha Iyer Rodrigues
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website zumutor.com
  • Social LinkedIn X Facebook
  • Legal Name Zumutor Biologics Inc
  • Date of Incorporation 31 Jul, 2015
  • Jurisdiction Bangalore, Karnataka, India
Key Metrics
  • Annual Revenue
    ₹4.63 Cr

    FY 2025 · -64% YoY

  • Net Loss
    -₹3.90 Cr

    FY 2025 · -84% margin

  • EBITDA
    -₹3.35 Cr

    FY 2025 · -72% margin

  • Total Equity Funding
    $35.19M (USD)

    in 9 rounds

  • Latest Funding Round
    $7.3M (USD), Series B

    Jun 2026

  • Investors
    Accel

    & 10 more

  • Employee Count
    23

Products & Services of Zumutor Biologics

Zumutor Biologics offers a comprehensive portfolio of products and services, including ZM008 and Monoclonal Antibodies.

ZM008
Immunotherapy

ZM008 is developed as an anti-LLT1 antibody therapy.

Monoclonal Antibodies
Biologics

Monoclonal antibodies are created for targeted therapeutic solutions.

Funding Insights of Zumutor Biologics

Zumutor Biologics has successfully raised a total of $35.19M across 9 strategic funding rounds. The most recent funding activity was a Series B round of $7.3 million completed in June 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $35.19M
  • Total Rounds 9
  • Last Round Series B β€” $7.3M
  • First Round $6M

    (Jun 2013)

  • Investors Count 11

All 9 funding rounds of Zumutor Biologics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jun 2026$7.3MSeries B––
Nov 2024$730,410Series A–Siana Capital, Anand Suresh Deshpande
–
Feb 2024$720,265Series A–Bharat Innovation Fund
–
Oct 2022$241,344Series A–Siana Capital
–
Dec 2021$6.2MSeries A–Siana Capital, Accel
–
Nov 2019$4MSeries A–Bharat Innovation Fund
Apr 2018$4MSeries A–Accel
–
Jun 2015$6MSeries A––
–
Jun 2013$6MSeed–Accel, Aarin Capital
–
Valuation history

11 investors in total: 7 institutional and 4 angel.

Investors in Zumutor Biologics

Zumutor Biologics has secured backing from 11 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Accel, Bharat Fund and Aarin Capital.

All
Venture Fund
Institutional
Angel
InvestorDescriptionFounded YearDomainLocation
Venture fund management focusing on deep tech and science investments in India.
2018sianacapital.comBengaluru, India
Accel is recognized as a leading venture capital firm.
1983accel.comPalo Alto, United States
Funding for IP-driven deep-tech and digitization-led inclusive solutions.
2017bharat.fundAhmedabad, India
Venture funding in technology-intensive businesses within healthcare, education, and India-centric markets.
2012aarincapital.comBengaluru, India
Tech focused Venture Capital firm investing globally
idgventures.comSan Francisco, United States
premjiinvest.com
India focused VC fund
1999kitven.comBengaluru, India

Anand Suresh Deshpande

unknown_9270509704ea48139

Sharad Sanghi

Founder of Netmagic Solutions, prominent angel investor in Indian tech startups
unknown_fbdf9f894e964ac4b

B S Ajai Kumar

unknown_3ec3476ba9cf4b178
Premium access

Investor details for Zumutor Biologics

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Zumutor Biologics Private Limited (Zumutor Biologics)

Zumutor Biologics Private Limited is the primary company behind Zumutor Biologics. The board of Zumutor Biologics Private Limited currently have 3 directors; the longest-serving is Maloy Ghosh, appointed in 2016. 6 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Maloy Ghosh
DIN 06402193
Whole-time director01 Oct 201610 yrs 1 moZumutor Biologics Private Limited
Kavitha Iyer Rodrigues
DIN 01800241
CEO01 Oct 201610 yrs 1 moZumutor Biologics Private Limited
Ashwin Raguraman
DIN 00879680
Nominee Director26 Aug 20215 yrs 2 moZumutor Biologics Private Limited

People of Zumutor Biologics

14 people are tracked at Zumutor Biologics (3 in leadership, 11 in board & advisors); the tracked headcount is 23.

NameRoleGroup
Co-Founder & CEOLeadership
Chief Scientific OfficerLeadership
Anirban Bhattacharya
CFOLeadership
Karthik Viswanathan
Scientific Board MemberBoard & advisors
Anurag Rathore
Scientific Board MemberBoard & advisors
Stephen Hodi
Scientific Board MemberBoard & advisors
Ana Anderson
Scientific Board MemberBoard & advisors
Narendra Chirmule
Scientific Board MemberBoard & advisors
Raghavan V
Scientific Board MemberBoard & advisors
Charles Cooney
Strategic AdvisorBoard & advisors
Mark Wolters
Strategic AdvisorBoard & advisors
Patrick Vink
Strategic AdvisorBoard & advisors
Andy Rakestraw
Scientific Board MemberBoard & advisors
Pradip Mazumdar
Scientific Board MemberBoard & advisors
Premium access

Complete people profiles for Zumutor Biologics

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Financials of Zumutor Biologics

Figures of Zumutor Biologics Private Limited, the primary company behind Zumutor Biologics, for FY 2025. Revenue was ₹4.63 Cr (-64% year on year). Net loss was -₹3.90 Cr (-84% margin). EBITDA was -₹3.35 Cr (-72% margin). Revenue has grown at a compounded annual rate of -42% over three years and -21% over five years.

  • ₹4.63 CrRevenue · FY 2025 · -64% YoY
  • -₹3.90 CrNet loss · -84% margin
  • -₹3.35 CrEBITDA · -72% margin
  • ₹1.2 LakhPaid-up capital
  • 23Employees (provident fund records)
  • -42%Revenue CAGR, 3 years
  • -21%Revenue CAGR, 5 years

Balance sheet, profit and loss, cash flow and ratios of Zumutor Biologics Private Limited are on its company page.

Premium access

Detailed financial statements for Zumutor Biologics

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Timeline of Zumutor Biologics

3 dated milestones of Zumutor Biologics across 13 years, from founding to its latest funding, stage changes and deals.

  1. Founded Zumutor Biologics is founded.
  2. Funding First funding round of $6.0M.
  3. Funding Latest funding round, Series B, of $7.3M.

Web traffic of Zumutor Biologics

The website of Zumutor Biologics (zumutor.com) receives about 1.5K visits a month.

  • Monthly visits
    1.5K

    ▲ 22.5% vs previous month

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Zumutor Biologics

Premium access

Complete news archive for Zumutor Biologics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Zumutor Biologics

Zumutor Biologics was founded in 2013.

Zumutor Biologics is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.

Kavitha Iyer Rodrigues is the CEO of Zumutor Biologics, as recorded in our data. They have also founded this company.

Zumutor Biologics is a funded company, having raised a total of $35.19M across 9 funding rounds to date. The company's 1st funding round was a Seed of $6M, raised on Jun 2013.

Zumutor Biologics has 23 employees.

The primary company behind Zumutor Biologics, Zumutor Biologics Private Limited, reported revenue of β‚Ή4.63 Cr for FY 2025, down 64% year on year.

Zumutor Biologics is engaged in the discovery and development of novel drug products, particularly in the field of immuno-oncology. The company specializes in targeted NK cell therapeutics using proprietary human antibody platforms like INABLR. Headquartered in Cambridge, MA, USA, with RD facilities in Bangalore, India, Zumutor is involved in creating first-in-class therapeutic antibodies that address innate immunity and tumor microenvironments. Additionally, bespoke services are offered to facilitate partners discovery programs and co-development of monoclonal antibodies.

Zumutor Biologics offers ZM008 and Monoclonal Antibodies.

Zumutor Biologics has 11 investors. Key investors include Accel, Bharat Fund, Aarin Capital, Karnataka Information Technology Venture Capital Fund, and Siana Capital.

Zumutor Biologics operates through Zumutor Biologics Private Limited.

The legal entities of Zumutor Biologics currently have 4 directors, including Ashwin Raguraman, Maloy Ghosh, Kavitha Iyer Rodrigues and others.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available